Preserving T cell / antigen presenting cell interactions via shared L-arginine

通过共享 L-精氨酸保留 T 细胞/抗原呈递细胞相互作用

基本信息

  • 批准号:
    10240447
  • 负责人:
  • 金额:
    $ 19.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Amino acids are important nutrients integral to the function of T cells – key cells necessary for optimal immune activity during infection, vaccination, and anti-tumor immunity, to name a few. Harnessing amino acid metabo- lism to regulate T cell function, therefore, is an intriguing and exciting avenue of research. Still, fundamental gaps in the field include 1) understanding intercellular communication driven by amino acids, and 2) determin- ing immune cell intrinsic necessities of amino acid acquisition. The applicant’s long-term goal is to define the interplay between amino acid metabolism and basic immune responses, providing new therapeutic avenues to manipulate immune activity. The objective of this study is to 1) identify how L-arginine acquisition and utiliza- tion is regulated in T cell / antigen presenting cell interactions when L-arginine synthesis is ablated in one, or both, cell populations, and 2) determine the T cell-intrinsic necessity of L-arginine synthesis when rescuing immune-deficient mice in a mycobacteria-infection model. The applicant’s laboratory will draw on their exper- tise in defining the contribution of L-arginine metabolism during virulent and attenuated mycobacterial infection. Specifically, the applicant has generated TCR-transgenic mice specific for the dominant Ag85b mycobacterial antigen that are unable to synthesize L-arginine from L-citrulline to test how T cell L-arginine synthesis regu- lates immune function in the context of mycobacterial stimulation (in vitro) or infection (in vivo). The central hypothesis is that antigen presenting cells provide synthesized L-arginine to CD4+ T cells, enabling their ex- pansion and effector function. The applicant will test the hypothesis in two related, but independent aims. In Aim 1, the applicant will address two questions: 1) how does L-arginine synthesis in antigen presenting cells impact T cell proliferation and cytokine production, and 2) can L-arginine synthesized from L-citrulline be found within CD4+ T cells intrinsically deficient in generating L-arginine? In Aim 2, the applicant will address if T cell- intrinsic L-arginine synthesis is necessary for host immunity to mycobacteria in vivo. The proposed research is significant and is expected to lead towards a better understanding of 1) amino acid mediated regulation of lym- phocyte function and 2) communication pathways vital to T cell / antigen presenting cell interactions, potentially exposing new avenues of host-directed therapy within, and outside the realm of host defense against infection. Uncovering the impact of “immunonutrition” is expected to advance the overall missions of the NIAID and NIH by seeking fundamental knowledge to understand and prevent infectious disease, providing new directions to enhance health and reduce illness.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph E Qualls其他文献

Joseph E Qualls的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph E Qualls', 18)}}的其他基金

L-citrulline and anti-tuberculosis host defense
L-瓜氨酸和抗结核宿主防御
  • 批准号:
    9304965
  • 财政年份:
    2016
  • 资助金额:
    $ 19.88万
  • 项目类别:
L-citrulline and anti-tuberculosis host defense
L-瓜氨酸和抗结核宿主防御
  • 批准号:
    9174922
  • 财政年份:
    2016
  • 资助金额:
    $ 19.88万
  • 项目类别:
Role of TAM Arginase 1 in Tumor Progression
TAM 精氨酸酶 1 在肿瘤进展中的作用
  • 批准号:
    7615323
  • 财政年份:
    2009
  • 资助金额:
    $ 19.88万
  • 项目类别:
Role of TAM Arginase 1 in Tumor Progression
TAM 精氨酸酶 1 在肿瘤进展中的作用
  • 批准号:
    7970929
  • 财政年份:
    2009
  • 资助金额:
    $ 19.88万
  • 项目类别:
Role of TAM Arginase 1 in Tumor Progression
TAM 精氨酸酶 1 在肿瘤进展中的作用
  • 批准号:
    8123466
  • 财政年份:
    2009
  • 资助金额:
    $ 19.88万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 19.88万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 19.88万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 19.88万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 19.88万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 19.88万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 19.88万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 19.88万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 19.88万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 19.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了